BACKGROUND: Juvenile neuronal ceroid lipofuscinosis (JNCL, NCL3, Batten disease) is usually caused by a 1.02-kb deletion in the CLN3 gene. Mutations in the CLN1 gene may be associated with a variant form of JNCL (vJNCL). We report the clinical course and molecular studies in 24 patients with JNCL collected from 1975 to 2010 with the aim of assessing the natural history of the disorder and phenotype/genotype correlations. PATIENTS AND METHODS: Patients were classified into the groups of vJNCL with mutations in the CLN1 gene and/or granular osmiophilic deposit (GROD) inclusion bodies (n = 11) and classic JNCL (cJNCL) with mutations in the CLN3 gene and/or fingerprint (FP) profiles (n = 13). Psychomotor impairment included regression of acquired skills, cognitive decline, and clinical manifestations of the disease. We used Kaplan-Meier analyses to estimate the age of onset of psychomotor impairment. RESULTS: Patients with vJNCL showed learning delay at an earlier age (median 4 years, 95% confidence interval [CI] 3.1-4.8) than those in the cJNCL group (median 8 years, 95% CI 6.2-9.7) (P = 0.001) and regression of acquired skills at a younger age. Patients with vJNCL showed a more severe and progressive clinical course than those with cJNCL. There may be a Gypsy ancestry for V181L missense mutation in the CLN1 gene. CONCLUSIONS: The rate of disease progression may be useful to diagnose vJNCL or cJNCL, which should be confirmed by molecular studies in CLN1/CLN3 genes. Further studies of genotype/phenotype correlation will be helpful for understanding the pathogenesis of this disease.
BACKGROUND:Juvenile neuronal ceroid lipofuscinosis (JNCL, NCL3, Batten disease) is usually caused by a 1.02-kb deletion in the CLN3 gene. Mutations in the CLN1 gene may be associated with a variant form of JNCL (vJNCL). We report the clinical course and molecular studies in 24 patients with JNCL collected from 1975 to 2010 with the aim of assessing the natural history of the disorder and phenotype/genotype correlations. PATIENTS AND METHODS: Patients were classified into the groups of vJNCL with mutations in the CLN1 gene and/or granular osmiophilic deposit (GROD) inclusion bodies (n = 11) and classic JNCL (cJNCL) with mutations in the CLN3 gene and/or fingerprint (FP) profiles (n = 13). Psychomotor impairment included regression of acquired skills, cognitive decline, and clinical manifestations of the disease. We used Kaplan-Meier analyses to estimate the age of onset of psychomotor impairment. RESULTS:Patients with vJNCL showed learning delay at an earlier age (median 4 years, 95% confidence interval [CI] 3.1-4.8) than those in the cJNCL group (median 8 years, 95% CI 6.2-9.7) (P = 0.001) and regression of acquired skills at a younger age. Patients with vJNCL showed a more severe and progressive clinical course than those with cJNCL. There may be a Gypsy ancestry for V181L missense mutation in the CLN1 gene. CONCLUSIONS: The rate of disease progression may be useful to diagnose vJNCL or cJNCL, which should be confirmed by molecular studies in CLN1/CLN3 genes. Further studies of genotype/phenotype correlation will be helpful for understanding the pathogenesis of this disease.
Authors: L Lauronen; P B Munroe; I Järvelä; T Autti; H M Mitchison; A M O'Rawe; R M Gardiner; S E Mole; J Puranen; A M Häkkinen; E Kirveskari; P Santavuori Journal: Neurology Date: 1999-01-15 Impact factor: 9.910
Authors: F J Marshall; E A de Blieck; J W Mink; L Dure; H Adams; S Messing; P G Rothberg; E Levy; T McDonough; J DeYoung; M Wang; D Ramirez-Montealegre; J M Kwon; D A Pearce Journal: Neurology Date: 2005-07-26 Impact factor: 9.910
Authors: K E Wisniewski; N Zhong; W Kaczmarski; A Kaczmarski; E Kida; W T Brown; K O Schwarz; A M Lazzarini; A J Rubin; E S Stenroos; W G Johnson; T M Wisniewski Journal: Ann Neurol Date: 1998-01 Impact factor: 10.422
Authors: Taina H Autti; Janne Hämäläinen; Minna Mannerkoski; Koen Van Van Leemput; Laura E Aberg Journal: J Neurol Date: 2008-07-17 Impact factor: 4.849
Authors: Julie Turnbull; Jean-Marie Girard; Hannes Lohi; Elayne M Chan; Peixiang Wang; Erica Tiberia; Salah Omer; Mushtaq Ahmed; Christopher Bennett; Aruna Chakrabarty; Atul Tyagi; Yan Liu; Nela Pencea; XiaoChu Zhao; Stephen W Scherer; Cameron A Ackerley; Berge A Minassian Journal: Brain Date: 2012-09 Impact factor: 13.501
Authors: Jonathan B Rosenberg; Alvin Chen; Stephen M Kaminsky; Ronald G Crystal; Dolan Sondhi Journal: Expert Opin Orphan Drugs Date: 2019-11-27 Impact factor: 0.694
Authors: Abdulhakim Jilani; Diana Matviychuk; Susan Blaser; Sarah Dyack; Jean Mathieu; Asuri N Prasad; Chitra Prasad; Lianna Kyriakopoulou; Saadet Mercimek-Andrews Journal: JIMD Rep Date: 2019-09-03
Authors: Juan C Zenteno; Leopoldo A García-Montaño; Marisa Cruz-Aguilar; Josué Ronquillo; Agustín Rodas-Serrano; Luis Aguilar-Castul; Rodrigo Matsui; Carlos I Vencedor-Meraz; Rocío Arce-González; Federico Graue-Wiechers; Mario Gutiérrez-Paz; Tatiana Urrea-Victoria; Ulises de Dios Cuadras; Oscar F Chacón-Camacho Journal: Mol Genet Genomic Med Date: 2019-11-17 Impact factor: 2.183